High dose opioid agonist therapy for patients with opioid use disorder: a case series exploring this patient-centered approach
Authors:
- 2 September 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 43 (4) , 386-393
Abstract
Management of opioid withdrawal in the inpatient setting can vary widely depending on the patient, the physician, and the institution. Although buprenorphine and methadone are first-line therapy for withdrawal management, some patients experience barriers to those medications. In this case series, we explore high dose opioid agonist therapy (HDOAT) as a novel and effective option to bridge to recovery in this particular setting. This retrospective case series includes- five patients with opioid use disorder (OUD) who were treated with HDOAT while hospitalized and reports on their outcomes. All five patients completed lifesaving medical therapy, engaged with community health workers for resources, and successfully transitioned to medications for opioid use disorder (MOUD). More importantly, none of the patients had patient directed discharges (PDDs). Furthermore, there were no inpatient drug uses or overdoses requiring naloxone administration, even with very high doses of oxycodone. None of the five patients were readmitted within thirty days. Although more rigorous research is needed, HDOAT may be a viable strategy for OUD when patients continued to decline buprenorphine or methadone on admission. This case series demonstrated the successful use of this strategy toward preventing PDDs, promoting treatment completion, and allowing substance recovery and rehabilitation, in patients who elected to defer MOUD on arrival.Keywords
This publication has 16 references indexed in Scilit:
- Quantitative Analysis of Characteristics Associated with Patient-Directed Discharges, Representations, and Readmissions: a Safety-Net Hospital ExperienceJournal of General Internal Medicine, 2023
- Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal?Journal of Hospital Medicine, 2023
- Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of FentanylJAMA Network Open, 2023
- Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: A thematic framework analysis of coroner reportsPLOS ONE, 2023
- Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorderAddiction Science & Clinical Practice, 2023
- Association of Early Opioid Withdrawal Treatment Strategy and Patient-Directed Discharge Among Hospitalized Patients with Opioid Use DisorderJournal of General Internal Medicine, 2023
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022MMWR. Recommendations and Reports, 2022
- Patients with Substance use Disorders Receiving Continued Care in Skilled Nursing Facilities following HospitalizationSubstance Abuse, 2022
- Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover studyPLOS Medicine, 2021
- Understanding why Patients with Substance use Disorders Leave the Hospital against Medical Advice: A Qualitative StudySubstance Abuse, 2019